Long-standing relapse of insulinoma in clinical practice
T.Yu. Demidova, V.V. Titova

Pirogov Russian National Research Medical University, Moscow

Insulinoma is the most frequent neuroendocrine tumor (up to 70–75% of the total), originating from β-cells of the Langerhans islets, secreting insulin into the bloodstream uncontrollably, which turn up as the cause of spontaneous hypoglycemia. Insulinomas are rare (1–4 cases per 1 million population per year) and in most cases (up to 90%) are benign, malignant insulinomas occur in 5–10% of cases. Diagnosis of insulinoma may be delayed for several years since the onset of the disease as the symptoms of the disease are nonspecific and may be similar to the symptoms of mental, cardiovascular and neurological diseases. Surgical resection is the main treatment of insulinoma. In benign single insulinoma, small in size, located in the corpus or cauda pancreatis, laparoscopic surgery, enucleation, partial or middle pancreatectomy are possible, which preserve the healthy tissue of the pancreas, thus reducing the risk of pancreatic function insufficiency.
The article presents a clinical case of relapse of insulinoma in a patient after an open treatment of long-term insulinoma without adequate therapy. The authors provide brief information about the endogenous hyperinsulinism as the manifestation of insulinoma.

Key words: endogenous hyperinsulinism, hypoglycemia, neuroendocrine tumor, insulinoma, pancreatectomy, laparoscopic surgery, clinical case.
For citation: Demidova T.Yu., Titova V.V. Long-standing relapse of insulinoma in clinical practice // RMJ. 2018. № 11(II). P. 122–125.